How to measure the impacts of antibiotic resistance and antibiotic development on empiric therapy: New composite indices

BMJ Open

Volumn 6, Issue 12, 2016, Pages

  Hughes, Josie S ^a   Hurford, Amy ^b   Finley, Rita L ^c   Patrick, David M ^d,e   Wu, Jianhong ^a   Morris, Andrew M ^f,g  

^a YORK UNIVERSITY   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

antimicrobial resistance; burden of resistance; composite index; cumulative antibiogram; device associated infection

Indexed keywords

AMIKACIN; AMPICILLIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; NITROFURANTOIN; OXACILLIN; POLYMYXIN; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASSESSMENT OF HUMANS; BACTERIAL STRAIN; CATHETER INFECTION; CENTRAL VENOUS CATHETER; EMPIRIC COVERAGE INDEX; EMPIRIC OPTION INDEX; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HEALTH CARE POLICY; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; KLEBSIELLA; KLEBSIELLA INFECTION; MECHANICAL VENTILATOR; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PROTEUS; PROTEUS INFECTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SERRATIA; SERRATIA INFECTION; URINARY CATHETER; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; CATHETER-RELATED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES;

EID: 85006754048     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-012040     Document Type: Article

References (60)

1. CDC: Centers for Disease Control and Prevention. Antibiotic Resistance Threats In The United States, 2013. 2013. http:// www.cdc.gov/drugresistance/threat-report-2013/ (accessed 26 May 2015).
2. WHO: World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. http://www.who.int/drugresistance/ documents/surveillancereport/en/ (accessed 26 May 2015).
3. CDDEP: The Center for Disease Dynamics E, Policy. The State of the World's Antibiotics, 2015. 2015. http://www.cddep.org/ publications/state-worlds-antibiotics-2015 (accessed 30 Sep 2015).
4. Doshi P. Speeding new antibiotics to market: a fake fix? BMJ 2015;350:h1453.
5. Timsit JF, Harbarth S, Carlet J. De-escalation as a potential way of reducing antibiotic use and antimicrobial resistance in ICU. Intensive Care Med 2014;40:1580-2.
6. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77.
7. Munoz-Price LS, Quinn JP. Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2013;26:378-87.
8. Tacconelli E, Cataldo MA, Dancer SJ, et al., European Society of Clinical Microbiology. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infec 2014;20(Suppl 1):1-55.
9. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013;13:1057-98.
10. Laxminarayan R, Klugman KP. Communicating trends in resistance using a drug resistance index. BMJ Open 2011;1:e000135.
11. Ciccolini M, Spoorenberg V, Geerlings SE, et al. Using an index-based approach to assess the population-level appropriateness of empirical antibiotic therapy. J Antimicrob Chemother 2015;70:286-93.
12. Patrick DM, Chambers C, Purych D, et al. Value of an aggregate index in describing the impact of trends in antimicrobial resistance for Escherichia coli. Can J Infect Dis Med Microbiol 2015;26:33-8.
13. Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: A new consensus guideline from the clinical and laboratory standards institute. Clin Infect Dis 2007;44: 867-73.
14. Marquet K, Liesenborgs A, Bergs J, et al. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care 2015;19:63.
15. Randhawa V, Sarwar S, Walker S, et al. Weighted-incidence syndromic combination antibiograms to guide empiric treatment of critical care infections: a retrospective cohort study. Crit Care 2014;18:R112.
16. Textoris J, Wiramus S, Martin C, et al. Overview of antimicrobial therapy in intensive care units. Expert Rev Anti Infect Ther 2011;9:97-109.
17. Ulldemolins M, Nuvials X, Palomar M, et al. Appropriateness is critical. Crit Care Clin 2011;27:35-51.
18. Burillo A, Bouza E. Use of rapid diagnostic techniques in ICU patients with infections. BMC Infect Dis 2014;14:593.
19. Laxminarayan R. Antibiotic effectiveness: balancing conservation against innovation. Science 2014;345:1299-301.
20. ILO: International Labour Organization. Consumer price index manual: theory and practice. Tech. rep. Geneva: International Labour Office, 2004.
21. Vincent JL, Rello J, Marshall J, et al., EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9.
22. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198-208.
23. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to The National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34:1-14.
24. PHAC: Public Health Agency of Canada. Central venous catheter-associated blood stream infections in intensive care units in Canadian acute-care hospitals: Surveillance report January 1, 2006 to December 31, 2006 and January 1, 2009 to December 31, 2011. Report. Public Health Agency of Canada, 2014.
25. Melsen WG, Rovers MM, Groenwold RH, et al. Pseudomonas aeruginosa: all roads lead to resistance. Intensive Care Med 2014;40:203-10.
26. CLSI: Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement M100-S19. Wayne, PA, USA: CLSI, 2013.
27. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infec 2012;18:268-81.
28. Jackson J, Chen C, Buising K. Aminoglycosides: how should we use them in the 21st century? Curr Opin Infect Dis 2013;26:516-25.
29. Becker B, Cooper MA. Aminoglycoside antibiotics in the 21st century. ACS Chem Biol 2013;8:105-15.
30. de With K, Allerberger F, Amann S, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection 2016;44:395-439.
31. Public Health Ontario. Antimicrobial Stewardship Strategy: Formulary restriction. 2016. http://www.publichealthontario.ca/en/ BrowseByTopic/InfectiousDiseases/ AntimicrobialStewardshipProgram/Documents/ASP-Strategy- Formulary-Restriction.pdf (accessed 01 Jul 2016).
32. Sanford JP, Gilbert DN, Moellering RCJ, et al, eds. The Sanford guide to antimicrobial therapy. 27th edn. Vienna, VA: Antimicrobial Therapy Inc., 1997.
33. Gilbert DN, Chambers HF, Eliopoulous GM et al, eds. The Sanford guide to antimicrobial therapy. 44th edn. Sperryville, VA: Antimicrobial Therapy Inc., 2014.
34. Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics. From salvarsan to cephalosporins. J Invest Surg 2012;25:67-77.
35. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997;24(Suppl 1):S19-45.
36. Arshad S, Hartman P, Zervos MJ. A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection. Expert Rev Anti Infect Ther 2014;12:727-9.
37. Sader HS, Farrell DJ, Flamm RK, et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014;69:266-77.
38. MSH: Mount Sinai Hospital. Antimicrobial susceptibility testing manual. 2013. http://www.mountsinai.on.ca/education/ staff-professionals/microbiology 39.
39. Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 2015;90:395-403.
40. Mendes RE, Farrell DJ, Flamm RK, et al. Analysis of Vancomycin susceptibility testing results for presumptive categorization of Telavancin. J Clin Microbiol 2015;53:2727-30.
41. Hebert C, Ridgway J, Vekhter B, et al. Demonstration of the weighted-incidence syndromic combination antibiogram: an empiric prescribing decision aid. Infect Control Hosp Epidemiol 2012;33:381-8.
42. Bielicki JA, Sharland M, Johnson AP, et al. Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data. J Antimicrob Chemother 2016;71:794-802.
43. Abel zur Wiesch P, Kouyos R, Abel S, et al. Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLOS Pathog 2014;10:e1004225.
44. Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents 2015;46:53-9.
45. Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014;69:2713-22.
46. Cerexa. Intravenous ceftazidime-avibactam (CAZ-AVI) for treatment in adults with cIAI and cUTI, HABP/VABP, or bacteremia where there are limited or no treatment options. 2014. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMateri Drugs/ Anti-InfectiveDrugsAdvisoryCommittee/UCM426700.pdf (accessed 11 May 2015).
47. Siegel JD, Rhinehart E, Jackson M, et al., Health Care Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;35(Suppl 2):S65-164.
48. Hiramatsu K, Cui L, Kuroda M, et al. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001;9:486-93.
49. Schechner V, Temkin E, Harbarth S, et al. Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev 2013;26:289-307.
50. Timsit JF, Laupland KB. Update on bloodstream infections in ICUs. Curr Opin Crit Care 2012;18:479-86.
51. Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intens Care Med 2012;38:1930-45.
52. Corona A, Bertolini G, Lipman J, et al. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010;65:1276-85.
53. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41:848-54.
54. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003;361:2068-77.
55. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
56. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45.
57. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625-63.
58. Spicknall IH, Foxman B, Marrs CF, et al. A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization. Am J Epidemiol 2013;178:508-20.
59. Otto SP, Day T. A biologists guide to mathematical modeling in ecology and evolution. Princeton, New Jersey: Princeton University Press, 2007.
60. Teillant A, Gandra S, Barter D, et al. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis 2015;15:1429-37.